Hjem
Lars Andreas Akslens bilde

Lars Andreas Akslen

Professor, Leder for CCBIO
  • E-postLars.Akslen@uib.no
  • Telefon+47 55 97 31 82
  • Besøksadresse
    Patologisk avdeling, Sentralblokka 2 etg., Haukeland Universitetssjukehus (HUS)
    evt. CCBIO, Sentralblokka 2 etg., HUS
  • Postadresse
    Postboks 7804
    5020 Bergen

Akslen er en sertifisert spesialist i kirurgisk patologi og leder forskningsgruppen Tumor Biology Research Group (etablert i 1995) ved Klinisk Institutt 1, Universitetet i Bergen. Siden 2013 har Akslen vært senterleder for Centre for Cancer Biomarkers CCBIO. Akslens gruppe og CCBIO arbeider med translasjonell kreftforskning med fokus på nye kreftmarkører og målrettet behandling og særlig mekanismer knyttet til hvordan kreftceller påvirkes av mikromiljøet i svulstene, og den betydning dette har for kreftspredning og dårlig prognose. Gruppen har prosjekter på ulike kreftformer, som brystkreft, ondartet melanom, prostatakreft og gynekologisk kreft. Gruppen kombinerer studier av humane tumorprøver med eksperimentelle celle- og dyremodeller. Det overordnede målet er å finne nye biomarkører som kan hjelpe oss til å forutse hvordan aggressive svulster vil utvikle seg og dermed bedre kunne skreddersy behandling.

Vitenskapelig artikkel
  • Vis forfatter(e) (2009). Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLOS ONE. 14 sider.
  • Vis forfatter(e) (2008). Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma research. 29-35.
  • Vis forfatter(e) (2008). HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. International Journal of Oncology. 307-316.
  • Vis forfatter(e) (2008). Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women. APMIS - Journal of Pathologiy, Microbiology and Immunology. 515-525.
  • Vis forfatter(e) (2007). ERG upregulation and related ETS transcription factors in prostate cancer. International Journal of Oncology. 19-32.
  • Vis forfatter(e) (2006). Vascular proliferation is important for clinical progress of endometrial cancer. Cancer Research. 3303-3309.
  • Vis forfatter(e) (2006). Role of angiogenesis in human tumor dormancy - Animal models of the angiogenic switch. Cell Cycle. 1779-1787.
  • Vis forfatter(e) (2006). Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. American Journal of Obstetrics and Gynecology. 979-986.
  • Vis forfatter(e) (2006). Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical 14 retropubic prostatectomy for localized prostate cancer? BJU International. 51-55.
  • Vis forfatter(e) (2006). Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid. 161-175.
  • Vis forfatter(e) (2006). Expression of bFGF/FGFR-1 and vascular proliferation related to clinicopathologic features and tumor progress in localized prostate cancer. Virchows Archiv. 68-74.
  • Vis forfatter(e) (2006). EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. Journal of Clinical Oncology. 268-273.
  • Vis forfatter(e) (2005). Predictors of prostate cancer evaluated by receiver operating characteristics partial area index: a prospective institutional study. Journal of Urology. 425-428.
  • Vis forfatter(e) (2005). Gene expression profiles in prostate cancer: Association with patient subgroups and tumour differentiation. International Journal of Oncology. 329-336.
  • Vis forfatter(e) (2005). BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. Journal of Investigative Dermatology. 312-317.
  • Vis forfatter(e) (2004). The prognostic implication of the basal-like (cyclin E-high/p27(low)/p53(+)/glomeruloid-microvascular-proliferation(+)) phenotype of BRCA1-related breast cancer. Cancer Research. 830-835.
  • Vis forfatter(e) (2004). Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. International Journal of Oncology. 1615-1623.
  • Vis forfatter(e) (2004). Prognostic impact of histological grade and vascular invasion compared with tumor cell proliferation in endometrial carcinoma of endometrioid type. Histopathology. 472-479.
  • Vis forfatter(e) (2004). Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. Journal of Clinical Oncology. 1242-1252.
  • Vis forfatter(e) (2004). Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population-based series. International Journal of Gynecological Cancer. 957-965.
  • Vis forfatter(e) (2004). Karnydanning og tumorkar som mål for kreftterapi. Tidsskrift for Den norske legeforening. 1919-1922.
  • Vis forfatter(e) (2004). Immunohistochemical and Clinical Characterization of the Basal-like Subtype of Invasive Breast Carcinoma. Clinical Cancer Research. 5367-5374.
  • Vis forfatter(e) (2004). Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. International Journal of Oncology. 1559-1565.
  • Vis forfatter(e) (2003). TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clinical Cancer Research. 5582-5588.
  • Vis forfatter(e) (2003). Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. APMIS - Journal of Pathologiy, Microbiology and Immunology. 1011-1018.
  • Vis forfatter(e) (2003). Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. European Journal of Cancer. 438-446.
  • Vis forfatter(e) (2003). Molecular assessment of depth of myometrial invasion in stage I endometrial cancer: a model based on K-ras mutation analysis. Gynecologic Oncology. 218-25.
  • Vis forfatter(e) (2003). MSI-low, a real phenomenon which varies in frequency among cancer types. Journal of Pathology. 389-94.
  • Vis forfatter(e) (2003). Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. Journal of the National Cancer Institute. 1482-85.
  • Vis forfatter(e) (2003). Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clinical Cancer Research. 1474-1479.
  • Vis forfatter(e) (2003). Benign growth of different prostate zones in aging men with slightly elevated PSA in whom prostate cancer has been excluded: a prospective study of 510 patients. Urology. 447-450.
  • Vis forfatter(e) (2002). Molecular pathogenesis and prognostic factors in endometrial carcinoma. APMIS - Journal of Pathologiy, Microbiology and Immunology. 673-689.
  • Vis forfatter(e) (2002). Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite instability: a population-based study. Clinical Cancer Research. 138-43.
  • Vis forfatter(e) (2002). Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma. Cancer. 2185-91.
  • Vis forfatter(e) (2002). Can we rely on pathologic parameters to define conservative treatment of papillary thyroid carcinoma? International Journal of Surgical Pathology. 267-272.
  • Vis forfatter(e) (2001). Maximum Ki-67 staining in prostate cancer provides independent prognostic information after radical prostatectomy. Anticancer Research. 7 sider.
  • Vis forfatter(e) (2001). Familial occurrence of nonmedullary thyroid cancer: a population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway. Cancer Epidemiology, Biomarkers and Prevention. 113-117.
  • Vis forfatter(e) (2001). Expression of oestrogen and progesterone receptorss, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African poplation. East African Medical Journal. 360-5.
  • Vis forfatter(e) (2001). Expression and alternative splicing of c-ret RNA in papillary thyroid carcinomas. Oncogene. 885-892.
  • Vis forfatter(e) (2000). Molecular portraits of human breast tumours. Nature. 747-52.
  • Vis forfatter(e) (2000). Frequent loss of p16 protein expression and high proliferative activity (Ki-67) in malignant melanoma from black Africans. Anticancer Research. 4857-62.
  • Vis forfatter(e) (1999). The PTEN gene is methylated in endometrial carcinoma and associated with advanced disease and microsattelite instability. (Abs. no. 207). American Journal of Human Genetics. S. 209.
  • Vis forfatter(e) (1999). TP53 as a predictor of response to chemotherpy in breast cancer. RSO Scientific Updates. 73-88.
  • Vis forfatter(e) (1999). TP53 as a predictor of response to chemotherapy in breast cancer. European School of Oncology Scientific Updates. 73-88.
  • Vis forfatter(e) (1999). Strong prognostic influence of reduced p16 protein expression in endometrial carcinomas. A large population based study. (Abstract no. 0-079). Virchows Archiv. 185.
  • Vis forfatter(e) (1999). Significance of tumor associated macrophages. VEGF and TSP-1 expression for tumor angiogenesis and prognosis in endometrial carcinomas. International Journal of Cancer. 539-543.
  • Vis forfatter(e) (1999). Significance of tumor associated macrophages, VEGF and TSP-1 for angiogenesis and prognosis of endometrial carcinoma. International Journal of Cancer. 538-43.
  • Vis forfatter(e) (1999). Prognostic value of tumor angiogenesis, Ki67, p53 and p21 protein expression - a population based endometrial carcinoma study. Journal of Clinical Oncology. 595-99.
  • Vis forfatter(e) (1999). Prognostic significance of tumor angiogenesis, Ki-67, p53 and p21 expression - a population-based endometrial carcinoma study. Journal of Clinical Oncology. 1382-1390.
  • Vis forfatter(e) (1999). Prognostic significance of angiogenesis, Ki-67, p53 and p21 expression - a population-based endometrial carcinoma study. International Journal of Oncology. 395-399.
  • Vis forfatter(e) (1999). Loss of nuclear expression of p16 protein correlates with increased tumor cell proliferation and poor patient outcome in patients with vertical growth phase melanoma. (Abstract no. P-487). Virchows Archiv. 314.
  • Vis forfatter(e) (1999). Influence of TP53 gene alterations and Her-2 expression on the respons to treatment with doxorubicin in locally advanced breast cancer. (Abs. no. 227). Breast Cancer Research and Treatment.
  • Vis forfatter(e) (1999). Enhanced expression of EGF-receptor and low frequency of ras mutations in X-ray-induced rat thyroid tumours. Virchows Archiv. 434-441.
  • Vis forfatter(e) (1999). Clinicopathological characteristics of melanomas of the hand. Journal of Hand Surgery - British and European Volume. 460-64.
  • Vis forfatter(e) (1999). Clinicopathological characteristics of melanomas of the hand. Journal of Hand Surgery - British and European Volume. 460-64.
  • Vis forfatter(e) (1999). Angiogenesis is prognostically important in vertical growth phase melanomas. International Journal of Oncology. 595-599.
  • Vis forfatter(e) (1998). Økt forekomst av kreft i skjoldkjertelen blant norske kvinner gift med fiskere. Tidsskrift for Den norske legeforening. 4202-4205.
  • Vis forfatter(e) (1998). Risk of primary childhood brain tumors related to birth characteristics: a Norwegian prospective study. International Journal of Cancer. 498-503.
  • Vis forfatter(e) (1998). Risk of primary childhood brain tumors related to birth characteristics: a Norwegian prospective study. International Journal of Cancer. 498-503.
  • Vis forfatter(e) (1998). Risk of primary childhood brain tumors related to birth characteristics: a Norwegian prospective study. International Journal of Cancer. 498-503.
  • Vis forfatter(e) (1998). Risk of primary childhood brain tumors related to birth characteristics: a Norwegian prospective study. International Journal of Cancer. 498-503.
  • Vis forfatter(e) (1998). Prognostic impact of morphometric nuclear grade in endometrial carcinoma. Cancer. 956-964.
  • Vis forfatter(e) (1998). Independent prognostic importance of microvessel density in endometrial carcinoma. British Journal of Cancer. 1140-1144.
  • Vis forfatter(e) (1998). Independent prognostic importance of microvessel density in endometrial carcinoma. British Journal of Cancer. 1140-1144.
  • Vis forfatter(e) (1998). Identification of high-risk patients by assessment of nuclear Ki67 expression in a prosepective study of endometrial carcinoma patients. Clinical Cancer Research. 2779-2785.
  • Vis forfatter(e) (1998). Frequent mutations of the p53 gene in cutaneous melanoma of the nodular type. International Journal of Cancer. 91-95.
  • Vis forfatter(e) (1998). Diagnostisk molekylærbiologi ved solide svulster: Thyreoideacancer. Tidsskrift for Den norske legeforening. 2199-2203.
  • Vis forfatter(e) (1998). Diagnostisk molekylærbiologi ved solide svulster - thyreoidea. Tidsskrift for Den norske legeforening. 2199-2203.
  • Vis forfatter(e) (1998). Decreased survival for nulliparous women with endometrial carcinoma. Is the relationship due to biology or behaviour? Cancer. 1328-1333.
  • Vis forfatter(e) (1997). Recurrent endometrial carcinoma and the value of routine follow-up. British Journal of Obstetrics and Gynaecology. 1302-1307.
  • Vis forfatter(e) (1997). Recurrence of endometrial carcinoma and the value of routine follow up. British Journal of Obstetrics and Gynaecology. 1302-1307.
  • Vis forfatter(e) (1997). Recurrence of endometrial carcinoma and the value of routine follow up. British Journal of Obstetrics and Gynaecology. 1302-1307.
  • Vis forfatter(e) (1997). Prognostisk betydning av tumorbiologiske markører ved kreft i livmorslimhinnen. Kreftnytt. 4-7.
  • Vis forfatter(e) (1997). Increased risk of thyroid cancer among Norwegian females married to fishery workers. British Journal of Cancer. 385-389.
  • Vis forfatter(e) (1997). Expression of p16 protein in prostatic adenocarcinomas, intraepithelial neoplasia and benign/hyperplastic glands. Urologic Oncology. 59-66.
  • Vis forfatter(e) (1997). Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • Vis forfatter(e) (1997). Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • Vis forfatter(e) (1997). Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. International Journal of Cancer. 535-540.
  • Vis forfatter(e) (1997). Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • Vis forfatter(e) (1997). Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • Vis forfatter(e) (1997). Absence of p21 Expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • Vis forfatter(e) (1996). Thyroid carcinomas with tall-cell and columnar-cell features (letter). Current Diagnostic Pathology. 67.
  • Vis forfatter(e) (1996). Spesific TP53 gene mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • Vis forfatter(e) (1996). Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • Vis forfatter(e) (1996). Relationship between mutations in the TP53 gene and De Novo resistance and early relapse following treatment with doxorubicin in patients with breast cancer. Nature Medicine. 811-814.
  • Vis forfatter(e) (1996). Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • Vis forfatter(e) (1996). Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; Clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • Vis forfatter(e) (1996). Primary organ-culture of non neoplastic and neoplastic thyroid tissue as multicellular spheroids. International Journal of Oncology. 1071-1078.
  • Vis forfatter(e) (1996). Independent prognostic importance of vascular invasion in nodular melanomas. Cancer. 1211-1219.
  • Vis forfatter(e) (1996). Incidence of thyroid cancer in New Caledonia, South Pacific, during 1985-1992 (letter). American Journal of Epidemiology. 1174.
  • Vis forfatter(e) (1996). Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Research. 1184-1188.
  • Vis forfatter(e) (1996). Cytoplasmatic localization of EGF receptor in papillary thyroid carcinomas: Association with the 150-kDa receptor forms. International Journal of Cancer. 161-167.
  • Vis forfatter(e) (1996). Aggressive thyroid carcinoma with predominant cribriform growth pattern. Pathology, Research and Practice.
  • Vis forfatter(e) (1995). Primary organ culture of non-neoplastic and neoplastic thyroid tissue multicellular spheroids. International Journal of Oncology. 1071-1078.
  • Vis forfatter(e) (1995). Primary organ culture of non-neoplastic and neoplastic thyroid tissue as multicellular spheroids. International Journal of Oncology. 1071-1078.
  • Vis forfatter(e) (1995). Primary organ culture of non-neoplastic and neoplastic thyroid tissue as multicellular spheroids. International Journal of Oncology. 1071-1078.
  • Vis forfatter(e) (1995). Oncoproteins and tumor progression in papillary thyroid carcinoma. Presence of epidermal growth factor receptor (EGF-R), c-erbB-2 protein, estrogen receptor related protein (p29), p21-ras protein and proliferation indicators in relation to tumor recurrences and patients survival. Cancer. 1643-1654.
  • Vis forfatter(e) (1995). Oncoproteins and tumor progression in papillary thyroid carcinoma. Presence of epidermal growth factor receptor (EGF-R), c-erbB-2 protein, estrogen receptor related protein (29), p21-ras protein and proliferation indicators in relation to tumor recurrences and patient survival. Cancer. 1643-1654.
  • Vis forfatter(e) (1995). Lack of diagnostic value of DNA content and p53 immunostaining in normal, hyperplastic and neoplastic parathyroid tissue. Oncology Reports. 69-72.
  • Vis forfatter(e) (1995). Histopatologiens betydning for vurdering av kreftforekomst og kreftårsaker. Tidsskrift for Den norske legeforening. 943-946.
  • Vis forfatter(e) (1994). Thyroid cancer: some aspects of epidemiology and etiological factors, pathological features and tumour biology. International Journal of Oncology. 931-942.
  • Vis forfatter(e) (1994). Ploidy and proliferative rates in carcinomas of the breast in Tanzania. East African Medical Journal. 195-198.
  • Vis forfatter(e) (1994). Ploidy and proliferative rates in carcinomas of the breast in Tanzania. East African Medical Journal. 195-198.
  • Vis forfatter(e) (1994). Kreft i skjoldbruskkjertelen - økning i yngre årskull. Kreftnytt. 4-6.
  • Vis forfatter(e) (1994). Increase of endo-and exo-peptidases in thyroid tumors. Oncol Rep. 953-956.
  • Vis forfatter(e) (1994). Increase of endo- and exo-peptidases in thyroid tumours. Oncol Rep. 953-956.
  • Vis forfatter(e) (1994). Increase of endo- and exo-peptidases in thyroid tumors. Oncol Rep. 953-956.
  • Vis forfatter(e) (1994). Etiologiske og patobiologiske aspekter ved malignt melanom. Tidsskrift for Den norske legeforening. 908-911.
  • Vis forfatter(e) (1993). Thyroid cancer in children in Norway 1953-1987. European Journal of Cancer. 365-366.
  • Vis forfatter(e) (1993). Prognostic importance of various clinicopathological features in papillary thyroid carcinoma. European Journal of Cancer. 44-51.
  • Vis forfatter(e) (1993). Prognostic importance of various clinicopathological features in papillary thyroid carcinoma. European Journal of Cancer. 44-51.
  • Vis forfatter(e) (1993). Prognostic importance of histologic grading in papillary thyroid carcinoma. Cancer. 2680-2685.
  • Vis forfatter(e) (1993). Prognostic impact of EGF-receptor in papillary thyroid carcinoma. British Journal of Cancer. 808-812.
  • Vis forfatter(e) (1993). Prognostic impact of EGF-receptor in papillary thyroid carcinoma. British Journal of Cancer. 808-812.
  • Vis forfatter(e) (1993). Incidence pattern of thyroid cancer in Norway: influence of birth cohort and time period. International Journal of Cancer. 183-187.
  • Vis forfatter(e) (1993). Demonstration of a TGF-_a-EGF receptor autocrine loop and c-myc protein overexpression in papillary thyroid carcinomas. International Journal of Cancer. 37-43.
  • Vis forfatter(e) (1992). Thyroid carcinoma. Results from surgical treatment in 211 consecutive patients. European Journal of Surgery. 521-526.
  • Vis forfatter(e) (1992). Second malignancies in thyroid cancer patients: a population-based survey of 3658 cases from Norway. European Journal of Cancer. 491-495.
  • Vis forfatter(e) (1992). Reproductive factors and risk of thyroid cancer. A prospective study of 63090 women from Norway. British Journal of Cancer. 772-774.
  • Vis forfatter(e) (1992). Expression of p53 protein in cutaneous melanoma. International Journal of Cancer. 13-16.
  • Vis forfatter(e) (1992). Expression of c-erbB-2 protein in papillary thyroid carcinomas. British Journal of Cancer. 832-837.
  • Vis forfatter(e) (1992). Disease free and cause specific survival in patients with papillary thyroid carcinoma. A multifactorial analysis. European Journal of Surgery. 583-589.
  • Vis forfatter(e) (1992). Differentiated thyroid carcinomas: the relevance of various pathological features for tumour classification and prediction of tumour progress. Virchows Archiv. A, Pathological anatomy and histopathology. 17-23.
  • Vis forfatter(e) (1991). Thyroid carcinoma: Results from surgical treatment in 211consecutive patients. European Journal of Surgery. 521-526.
  • Vis forfatter(e) (1991). Thyroid carcinoma. Results from a uniform surgical strategy 1971-1985. Acta Chirurgica Scandinavica. 521-526.
  • Vis forfatter(e) (1991). Survival and cause of death in thyroid cancer: A population-based study of 2479 cases from Norway. Cancer Research. 1234-1241.
  • Vis forfatter(e) (1991). Squamous cell carcinoma of the urinary bladder. Scandinavian Journal of Urology and Nephrology. 275-276.
  • Vis forfatter(e) (1991). Radical radiation treatment of invasive and locally advanced bladder carcinoma in elderly patients. British Journal of Urology. 61-69.
  • Vis forfatter(e) (1991). Periodicity in metastatic tumour growth demonstrated in human liver at autopsy. Invasion Metastasis. 58-64.
  • Vis forfatter(e) (1990). Provocation of thyroid neoplasms in female Wistar rats fed n-3 or n-6 fatty acids in the feed. Thyroidology. 1-3.
  • Vis forfatter(e) (1990). Increased content of chronium and nickel in lung tissues patients with bronchial carcinoma. Pathology, Research and Practice. 717-722.
  • Vis forfatter(e) (1989). Lifestyle and mortality among Norwegian men. Preventive Medicine. 433-443.
  • Vis forfatter(e) (1988). Life-style and caridovascular mortality among Norwegian men (Abstract). Circulation. 479.
Vitenskapelig foredrag
  • Vis forfatter(e) (2016). Molecular subtypes of breast cancer: long-term incidence trends and prognostic differences.
  • Vis forfatter(e) (2016). FGD5 amplification in breast cancer patients is associated with tumour proliferation and a poorer prognosis.
  • Vis forfatter(e) (2013). Molekylære subtyper og overlevelse ved brystkreft.
  • Vis forfatter(e) (2013). Molekylære subtyper og overlevelse ved brystkreft.
  • Vis forfatter(e) (2012). Multimodal imaging for suspected recurrent differentiated thyroid cancer (DTC): FDG-PET-CT, I-131-SPECT-CT, ultrasound (US) and US-guided fine needle biopsy (FNB).
  • Vis forfatter(e) (2011). Multimodal imaging for diagnosis and treatment of recurrent differentiated thyroid cancer (DTC)FDG-PET-CT, contrast-enhanced CT (CE-CT), I-131-SPECT-CT, ultrasound (US) and US-guided fine needle biopsy (FNB).
  • Vis forfatter(e) (2011). In vivo Dynamic Contrast Enhanced MRI & Histopathological Assessment of Tumor Angiogenesis in Luminal-like and Basal-like Breast Cancer Xenografts.
  • Vis forfatter(e) (2011). FDG-PET-CT, I-131-SPECT-CT, ultrasound (US) and US-guided fine needle biopsy (FNB) for recurrent differentiated thyroid cancer (DTC).
  • Vis forfatter(e) (2011). Early vascular response to bevacizumab treatment measured by DCE-MRI in breast cancer xenografts.
  • Vis forfatter(e) (2011). DCE-MRI for early therapy monitoring of anti-angiogenic therapy.
  • Vis forfatter(e) (2010). Real time elastografi ved cancer prostatae.
  • Vis forfatter(e) (2010). Preliminære resultater av PCA3 måling i urin hos pasienter med cancer prostatae.
  • Vis forfatter(e) (2010). Multimodal imaging of differentiated thyroid cancer: FDG-PET-CT, I-131-SPECT-CT and ultrasound.
  • Vis forfatter(e) (2010). In vivo magnetic resonance imaging and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts.
  • Vis forfatter(e) (2010). Er preoperativ MR-prostata nyttig for å avklare korrekt T-stadium forut for kirurgi?
  • Vis forfatter(e) (2010). Er MR-prostata nyttig for å avklare videre oppfølgningsbehov hos pasienter med 2 eller flere negative biopsiserier?
  • Vis forfatter(e) (2009). Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.
  • Vis forfatter(e) (2009). EMT Promotes Malignant Transformation of Prostate Epithelial Cells in Culture.
  • Vis forfatter(e) (2008). Polycomb group target genes and bivalent H3K4 & K27me3 modifications in human embryonic cells were enriched among dysregulated genes in prostate cancer.
  • Vis forfatter(e) (2008). Epithelial to mesenchymal transition of a primary, immortalized prostate cell line is associated with gene expression switches of entire cell attachment modules.
  • Vis forfatter(e) (2007). Functional oncogenomics and epigenomics analysis of prostate cancer.
  • Vis forfatter(e) (2007). Detection of TMPRSS2:ERG translocations in the urine of prostate cancer patients and identification of ERG target genes.
  • Vis forfatter(e) (2006). Global gene expression analysis of transcription factors in prostate cancer and cell lines.
  • Vis forfatter(e) (2006). ERG upregulation and related transcription factors in prostate cancer.
  • Vis forfatter(e) (2004). Gene expression profiling in prostate cancer refined by pairwise comparisons of cDNA microarrays from benign and malignant tissue.
  • Vis forfatter(e) (2004). Gene expression profiles in prostate cancer: identification of upregulated SIM2 gene validated in archival tissue, relation to histological grading and prognosis.
  • Vis forfatter(e) (2003). Mutation analysis of the RAS-RAF pathway in pancreatic adenocarcinomas and malignant melanomas.
  • Vis forfatter(e) (2003). Global analysis of gene expression and regulatory patterns in urogenital tumours using DNA microarrays.
  • Vis forfatter(e) (2003). Global analysis of gene expression and regulatory patterns in cancer.
  • Vis forfatter(e) (2003). Gene expression profiling in prostate cancer: cluster analysis and association with tumor differentation.
  • Vis forfatter(e) (2003). Gene expression profiling in prostate cancer: Cluster analysis and association with tumor differentiation.
  • Vis forfatter(e) (2003). Gene expression profiling in prostate cancer.
  • Vis forfatter(e) (2003). DNA microarray studies of human cancer - pitfalls and outlook.
  • Vis forfatter(e) (2003). Comparison of DNA microarray and real time quantitative PCR for quantitation of gene expression of selected genes in prostate cancer.
  • Vis forfatter(e) (2002). Cancer mammae behandlet med brystbevarende kirurgi ved Haukeland sykehus 1984-1995.
  • Vis forfatter(e) (2001). Prognostisk betydning av angiogenese (microvessel density - MVD) og proliferasjonsmarkøren Ki-67 ved lokalisert prostatacencer.
  • Vis forfatter(e) (1999). Prognostic importance of microvessel density (MVD) in clinically localized prostate cancer.
  • Vis forfatter(e) (1998). Prognostic importance of microvessel density (MVD) in clinically localized prostate cancer.
  • Vis forfatter(e) (1998). Profylaktisk thyroidectomi hos barn - initial erfaring.
  • Vis forfatter(e) (1998). Malignt melanom på hender.
  • Vis forfatter(e) (1998). Malignant melanoma of the hand. A 25-year clinico-pathological study.
  • Vis forfatter(e) (1997). Independent prognostic importance of microvessel density in endometrial carcinoma. [poster].
  • Vis forfatter(e) (1989). Mortality form ischemic heart disease related to life-style differences among Norwegian men (Abstract).
Vitenskapelig antologi/Konferanseserie
  • Vis forfatter(e) (2017). Biomarkers of the Tumor Microenvironment: Basic Studies and Practical Applications. Springer.
Sammendrag/abstract
  • Vis forfatter(e) (2013). Proliferation markers PHH3, Ki67 and mitotic count all show significant associations with features of aggressive breast carcinomas and reduced survival. Modern Pathology. 50A-50A.
  • Vis forfatter(e) (2013). Proliferation markers PHH3, Ki67 and Mimtotic count all show significant associations with features of aggressive breast carcinomas and reduced survival. Laboratory Investigation. 50A-50A.
  • Vis forfatter(e) (2013). FOXA1 LOSS IN ENDOMETRIAL CANCER IS ASSOCIATED WITH POOR PROGNOSIS AND ER ALPHA LOSS. International Journal of Gynecological Cancer. 1 sider.
  • Vis forfatter(e) (2012). Prognostic impact of proliferation markers Ki-67, PHH3 and mitotic count in breast carcinomas. Virchows Archiv. S5-S5.
  • Vis forfatter(e) (2012). Metabolic Responses to VEGF Inhibition in Patient-derived Breast Cancer Xenografts. European Journal of Cancer. S32-S32.
  • Vis forfatter(e) (2012). Expression of hypoxia-inducible factor-1a and associations with vascular endothelial growth factor expression, high microvessel density and features of aggressive tumors in African breast cancer. Virchows Archiv. S249-S249.
  • Vis forfatter(e) (2012). Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. Virchows Archiv. S18-S18.
  • Vis forfatter(e) (2011). Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Clinical and Experimental Metastasis. 234-235.
  • Vis forfatter(e) (2010). Prognostic importance of vascular proliferation and tumor cell invasion in blood and lymphatic vessels in endometrial carcinoma. APMIS - Journal of Pathologiy, Microbiology and Immunology. 248-248.
  • Vis forfatter(e) (2010). Multimodal imaging of differentiated thyroid cancer: FDG-PET-CT, I-131-SPECT-CT and ultrasound [Abstract]. European Journal of Nuclear Medicine and Molecular Imaging. S291-S291.
  • Vis forfatter(e) (2009). Proliferation of immature tumor vessels is a novel marker of clinical progress in prostate cancer. APMIS - Journal of Pathologiy, Microbiology and Immunology. 233-233.
  • Vis forfatter(e) (2008). Vascular proliferation by Nestin/Ki-67 is a novel predictor of the clinical progress of prostate cancer. Histopathology. 276-277.
  • Vis forfatter(e) (2008). Candidate stem cell marker ALDH1 expression and relationship with BRCA-mutations and basal-like differentiation in breast carcinoma. Histopathology. 25-25.
  • Vis forfatter(e) (2007). Loss of BMI-1 expression is associated with the clinical progress of malignant melanoma. Virchows Archiv. 452-452.
  • Vis forfatter(e) (2007). Epithelial to mesenchymal transition is of strong prognostic importance in prostate cancer. Virchows Archiv. 344-344.
  • Vis forfatter(e) (2007). Basal-like phenotype is frequent in invasive breast carcinoma from Ugandan Africans and is strongly associated with a high expression of EGFR/c-Kit and features of aggressive tumors. Virchows Archiv. 137-137.
  • Vis forfatter(e) (2006). Global gene expression analysis of transcription factors in prostate cancer and cell lines. International Journal of Molecular Medicine. S27.
  • Vis forfatter(e) (2006). ERG upregulation in relation to other transcription factors in prostate cancer. NBS-nytt. 72.
  • Vis forfatter(e) (2005). Single-minded 2 homolog gene is overexpressed in prostate cancer. Virchows Archiv. 432-432.
  • Vis forfatter(e) (2005). Overexpression of ERG and SIM2 transcription factors in prostate cancer. International Journal of Molecular Medicine. S76-S76.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) (2013). Malignt melanom – diagnostikk, behandling og oppfølging i Norge. Tidsskrift for Den norske legeforening. 2154-2159.
  • Vis forfatter(e) (2009). Biologic markers in endometrial cancer treatment. APMIS - Journal of Pathologiy, Microbiology and Immunology. 693-707.
  • Vis forfatter(e) (2008). Tumor-vascular interactions and tumor dormancy. APMIS - Journal of Pathologiy, Microbiology and Immunology. 569-585.

Se fullstendig oversikt over publikasjoner i CRIStin.